BioNTech - BNTX Stock Price Target and Predictions

Target and Analyst Ratings
Price Target History
Upgrades and Downgrades
News Sentiment
About
FAQ

Consensus Rating: Hold
Consensus Price Target: $120.40
Forecasted Upside: 36.68%
Number of Analysts: 10
Breakdown:
1 Sell Ratings
5 Hold Ratings
4 Buy Ratings
0 Strong Buy Ratings

^$88.09 As of 04/24/2024 06:12 PM ET

▼ -0.4 (-0.45%)

1 month | 3 months | 12 months

Get New BioNTech Analyst Ratings Delivered To Your Inbox

Sign-up to receive the latest news and ratings for BNTX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for BNTX

^$120.40

▲ +36.68% Upside Potential

This price target is based on 10 analysts offering 12 month price targets for BioNTech in the last 3 months. The average price target is $120.40, with a high forecast of $171.00 and a low forecast of $90.00. The average price target represents a 36.68% upside from the last price of $88.09.

Current Consensus is Hold

The current consensus among 10 polled investment analysts is to hold stock in BioNTech. This Hold consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

0 strong buy ratings
4 buy ratings
5 hold ratings
1 sell ratings

Ratings as of

10/31/2022

0 strong buy ratings
4 buy ratings
5 hold ratings
1 sell ratings

Ratings as of

1/29/2023

0 strong buy ratings
4 buy ratings
5 hold ratings
1 sell ratings

Ratings as of

4/29/2023

0 strong buy ratings
4 buy ratings
5 hold ratings
1 sell ratings

Ratings as of

7/28/2023

0 strong buy ratings
4 buy ratings
5 hold ratings
1 sell ratings

Ratings as of

10/26/2023

0 strong buy ratings
4 buy ratings
5 hold ratings
1 sell ratings

Ratings as of

1/24/2024

0 strong buy ratings
4 buy ratings
5 hold ratings
1 sell ratings

Ratings as of

3/24/2024

0 strong buy ratings
4 buy ratings
5 hold ratings
1 sell ratings

Ratings as of

4/23/2024

Latest Recommendations

Show Most Recent Rating from Each Ratings Firm Show All Ratings

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price
4/17/2024	HC Wainwright	Reiterated Rating	Buy ➝ Buy	$107.00	Low
3/27/2024	UBS Group	Lower Target	Neutral ➝ Neutral	$110.00 ➝ $101.00	Low
3/22/2024	JPMorgan Chase & Co.	Lower Target	Underweight ➝ Underweight	$99.00 ➝ $90.00	Low
3/21/2024	BMO Capital Markets	Lower Target	Outperform ➝ Outperform	$127.00 ➝ $123.00	Low
3/21/2024	Canaccord Genuity Group	Reiterated Rating	Buy ➝ Buy	$171.00	Low
2/28/2024	The Goldman Sachs Group	Lower Target	Neutral ➝ Neutral	$113.00 ➝ $100.00	Low
2/23/2024	BMO Capital Markets	Initiated Coverage	Outperform	$127.00	Low
2/20/2024	Canaccord Genuity Group	Boost Target	Buy ➝ Buy	$168.00 ➝ $171.00	Low
1/23/2024	HC Wainwright	Lower Target	Buy ➝ Buy	$133.00 ➝ $107.00	Low
1/5/2024	Oppenheimer	Initiated Coverage	Market Perform		Low
12/1/2023	JPMorgan Chase & Co.	Downgrade	Neutral ➝ Underweight	$106.00 ➝ $99.00	Low
11/27/2023	HC Wainwright	Reiterated Rating	Buy ➝ Buy	$133.00	Low
11/14/2023	HC Wainwright	Lower Target	Buy ➝ Buy	$180.00 ➝ $133.00	Low
11/8/2023	Morgan Stanley	Boost Target	Equal Weight ➝ Equal Weight	$110.00 ➝ $111.00	Low
10/17/2023	Morgan Stanley	Lower Target	Equal Weight ➝ Equal Weight	$116.00 ➝ $110.00	Low
10/16/2023	HSBC	Downgrade	Buy ➝ Hold	$124.00 ➝ $111.00	Low
8/28/2023	HC Wainwright	Reiterated Rating	Buy ➝ Buy	$180.00	Low
8/10/2023	HC Wainwright	Lower Target	Buy ➝ Buy	$181.00 ➝ $180.00	N/A
8/8/2023	Morgan Stanley	Lower Target	Equal Weight ➝ Equal Weight	$119.00 ➝ $116.00	Low
7/31/2023	Morgan Stanley	Reiterated Rating	Equal Weight ➝ Equal Weight	$119.00	Low
7/24/2023	Morgan Stanley	Reiterated Rating	Equal Weight ➝ Equal Weight	$119.00	Low
7/14/2023	HSBC	Initiated Coverage	Buy	$124.00	Low
6/1/2023	HC Wainwright	Lower Target		$198.00 ➝ $181.00	Low
5/23/2023	HC Wainwright	Lower Target		$210.00 ➝ $198.00	Low
5/18/2023	Deutsche Bank Aktiengesellschaft	Lower Target		$135.00 ➝ $120.00	Low
5/17/2023	Redburn Partners	Upgrade	Neutral ➝ Buy	$165.00 ➝ $170.00	Low
4/10/2023	JPMorgan Chase & Co.	Lower Target	Neutral	$142.00 ➝ $128.00	Low
3/31/2023	UBS Group	Lower Target	Neutral	$168.00 ➝ $153.00	N/A
3/30/2023	HC Wainwright	Reiterated Rating	Buy	$210.00	Low
3/28/2023	Canaccord Genuity Group	Boost Target	Buy	$191.00 ➝ $203.00	Low
3/28/2023	TD Cowen	Lower Target	Market Perform	$145.00 ➝ $130.00	Low
3/28/2023	The Goldman Sachs Group	Set Target	Neutral	$156.00 ➝ $140.00	Low
3/28/2023	Berenberg Bank	Set Target		$260.00	Low
3/28/2023	Morgan Stanley	Lower Target	Equal Weight	$216.00 ➝ $150.00	Low
3/28/2023	Jefferies Financial Group	Set Target		$145.00	Low
3/27/2023	Bank of America	Lower Target	Buy	$239.00 ➝ $194.00	Low
3/23/2023	HC Wainwright	Lower Target	Buy	$272.00 ➝ $210.00	Low
2/8/2023	JPMorgan Chase & Co.	Lower Target	Neutral	$148.00 ➝ $142.00	Low
2/1/2023	UBS Group	Set Target		$168.00	Low
1/31/2023	The Goldman Sachs Group	Lower Target	Neutral	$177.00 ➝ $156.00	Low
1/30/2023	Berenberg Bank	Set Target		$300.00	Low
1/24/2023	Morgan Stanley	Boost Target	Equal Weight	$203.00 ➝ $216.00	Low
1/16/2023	The Goldman Sachs Group	Set Target		$177.00	Low
1/11/2023	JPMorgan Chase & Co.	Set Target		$148.00	Low
12/15/2022	Bank of America	Upgrade	Neutral ➝ Buy	$239.00	Low
11/21/2022	JPMorgan Chase & Co.	Set Target		$148.00	Low
11/15/2022	UBS Group	Set Target		$168.00	Low
11/8/2022	Berenberg Bank	Set Target		$312.00	Low
11/8/2022	Morgan Stanley	Boost Target	Equal Weight	$194.00 ➝ $203.00	Low
11/8/2022	Canaccord Genuity Group	Lower Target	Buy ➝ Buy	$200.00 ➝ $191.00	Low
11/8/2022	The Goldman Sachs Group	Lower Target	Neutral	$200.00 ➝ $177.00	Low
10/24/2022	JPMorgan Chase & Co.	Lower Target	Neutral	$183.00 ➝ $132.00	Low
10/21/2022	Berenberg Bank	Set Target		$312.00	Low
9/27/2022	Berenberg Bank	Set Target		$312.00	Low
9/8/2022	Deutsche Bank Aktiengesellschaft	Set Target		$180.00	Low
9/8/2022	Berenberg Bank	Set Target		$312.00	Low
8/17/2022	Cowen	Initiated Coverage	Market Perform	$177.00	Low
8/17/2022	Cowen	Initiated Coverage	Market Perform		Low
8/10/2022	HC Wainwright	Lower Target	Buy	$283.00 ➝ $272.00	Low
8/9/2022	The Goldman Sachs Group	Set Target		$200.00	Low
8/9/2022	Berenberg Bank	Set Target		$312.00	Low
8/9/2022	Canaccord Genuity Group	Boost Target	Buy ➝ Buy	$192.00 ➝ $200.00	Low
7/29/2022	SVB Leerink	Boost Target	Outperform	$223.00 ➝ $224.00	Low
7/15/2022	Morgan Stanley	Lower Target	Equal Weight	$195.00 ➝ $194.00	Low
7/13/2022	SVB Leerink	Upgrade	Market Perform ➝ Outperform	$253.00 ➝ $223.00	Low
7/11/2022	HC Wainwright	Lower Target	Buy	$298.00 ➝ $283.00	N/A
7/6/2022	Canaccord Genuity Group	Reiterated Rating	Buy	$192.00	N/A
7/1/2022	Deutsche Bank Aktiengesellschaft	Set Target		$180.00	Low
6/30/2022	The Goldman Sachs Group	Set Target		$209.00	Low
6/30/2022	UBS Group	Set Target		$168.00	Low
6/15/2022	The Goldman Sachs Group	Set Target		$206.00	Low
5/24/2022	The Goldman Sachs Group	Lower Target	Neutral	$255.00 ➝ $206.00	Low
5/11/2022	The Goldman Sachs Group	Set Target		$255.00	Medium
5/10/2022	JPMorgan Chase & Co.	Set Target		$183.00	High
5/9/2022	Jefferies Financial Group	Set Target		$230.00	Low
4/12/2022	HC Wainwright	Lower Target	Buy	$339.00 ➝ $298.00	Medium
4/12/2022	Morgan Stanley	Lower Target	Equal Weight	$217.00 ➝ $197.00	Low
4/11/2022	Berenberg Bank	Reiterated Rating	Buy	$350.00	Low
4/5/2022	Canaccord Genuity Group	Lower Target	Buy	$450.00 ➝ $300.00	Medium
4/5/2022	UBS Group	Lower Target	Buy ➝ Buy	$450.00 ➝ $300.00	Low
4/5/2022	Berenberg Bank	Set Target		$400.00	N/A
4/1/2022	The Goldman Sachs Group	Set Target		$255.00	High
4/1/2022	Deutsche Bank Aktiengesellschaft	Set Target		$200.00	High
3/31/2022	JPMorgan Chase & Co.	Set Target		$183.00	Low
3/30/2022	Jefferies Financial Group	Set Target		$230.00	High
3/18/2022	Jefferies Financial Group	Set Target		$230.00	Medium
2/23/2022	HC Wainwright	Lower Target	Buy	$366.00 ➝ $339.00	High
2/14/2022	HC Wainwright	Reiterated Rating	Buy	$366.00	High
2/1/2022	Morgan Stanley	Lower Target	Equal Weight	$284.00 ➝ $217.00	Medium
2/1/2022	Redburn Partners	Upgrade	Sell ➝ Neutral		Low
1/19/2022	HC Wainwright	Reiterated Rating	Buy	$366.00	High
1/18/2022	Morgan Stanley	Lower Target	Equal Weight	$294.00 ➝ $284.00	High
1/12/2022	The Goldman Sachs Group	Set Target		$299.00	Low
1/5/2022	Berenberg Bank	Set Target		$400.00	Low
1/4/2022	HC Wainwright	Reiterated Rating	Buy	$366.00	Medium
12/22/2021	UBS Group	Upgrade	Neutral ➝ Buy		High
12/21/2021	HC Wainwright	Boost Target	Buy	$360.00 ➝ $366.00	High
12/16/2021	Morgan Stanley	Initiated Coverage	Equal Weight	$294.00	Medium
12/9/2021	Deutsche Bank Aktiengesellschaft	Set Target		$225.00	Medium
12/8/2021	Berenberg Bank	Set Target		$400.00	Low
12/8/2021	Jefferies Financial Group	Set Target		$230.00	Low
12/6/2021	Bank of America	Boost Target	Neutral ➝ Neutral	$341.00 ➝ $349.00	High
11/29/2021	Berenberg Bank	Set Target		$400.00	Low
11/22/2021	Jefferies Financial Group	Set Target		$230.00	High
11/10/2021	HC Wainwright	Upgrade	Neutral ➝ Buy	$242.00 ➝ $360.00	Medium
11/10/2021	JPMorgan Chase & Co.	Set Target		$180.00	Low
11/9/2021	Jefferies Financial Group	Set Target		$230.00	High
10/22/2021	Deutsche Bank Aktiengesellschaft	Initiated Coverage	Hold	$250.00	High
10/7/2021	Jefferies Financial Group	Set Target		$230.00	High
10/6/2021	Jefferies Financial Group	Initiated Coverage	Hold	$230.00	High
10/5/2021	HC Wainwright	Reiterated Rating	Hold	$330.00	Low
10/5/2021	Berenberg Bank	Set Target		$400.00	Low
10/5/2021	SVB Leerink	Lower Target	Market Perform	$293.00 ➝ $268.00	Low
10/5/2021	Bryan, Garnier & Co	Set Target		$359.00	Low
9/29/2021	HC Wainwright	Reiterated Rating	Hold	$330.00	Low
9/29/2021	The Goldman Sachs Group	Set Target		$433.00	Low
9/24/2021	Bryan, Garnier & Co	Set Target		$451.00	High
9/23/2021	UBS Group	Set Target		$300.00	Low
9/23/2021	The Goldman Sachs Group	Set Target		$433.00	Low
9/21/2021	HC Wainwright	Reiterated Rating	Hold	$330.00	Low
8/31/2021	HC Wainwright	Reiterated Rating	Hold	$330.00	Medium
8/27/2021	UBS Group	Boost Target	Neutral	$111.00 ➝ $300.00	Medium
8/13/2021	SVB Leerink	Boost Target	Market Perform	$159.00 ➝ $293.00	Low
8/11/2021	HC Wainwright	Boost Target	Neutral	$194.00 ➝ $330.00	High
8/11/2021	Bryan, Garnier & Co	Upgrade	Neutral ➝ Buy		High
8/8/2021	The Goldman Sachs Group	Downgrade	Buy ➝ Neutral		High
7/22/2021	SVB Leerink	Reiterated Rating	Hold		Low
7/20/2021	HC Wainwright	Reiterated Rating	Hold	$194.00	High
7/19/2021	Wolfe Research	Initiated Coverage	Outperform	$248.00	High
7/14/2021	HC Wainwright	Reiterated Rating	Hold	$194.00	Low
6/23/2021	SVB Leerink	Reiterated Rating	Hold		Medium
6/16/2021	Redburn Partners	Reiterated Rating	Neutral ➝ Sell	$146.00	High
5/18/2021	The Goldman Sachs Group	Initiated Coverage	Neutral	$173.00	Low
5/17/2021	Bryan, Garnier & Co	Reiterated Rating	Buy ➝ Neutral	$135.00 ➝ $206.00	N/A
5/11/2021	SVB Leerink	Boost Target	Positive ➝ Market Perform	$118.00 ➝ $159.00	Low
5/11/2021	Bryan, Garnier & Co	Downgrade	Buy ➝ Neutral	$135.00 ➝ $206.00	Low
4/13/2021	SVB Leerink	Boost Target	Market Perform	$110.00 ➝ $118.00	High
4/6/2021	SVB Leerink	Boost Target	Market Perform	$106.00 ➝ $110.00	Low
4/6/2021	Berenberg Bank	Set Target	Buy	$130.00	Medium
4/6/2021	JPMorgan Chase & Co.	Set Target	Neutral	$104.00	Medium
3/31/2021	JPMorgan Chase & Co.	Reiterated Rating	Neutral	$104.00	Low
3/31/2021	Berenberg Bank	Reiterated Rating	Buy	$130.00	Medium
2/4/2021	SVB Leerink	Boost Target	Market Perform	$97.00 ➝ $106.00	Low
1/11/2021	Berenberg Bank	Set Target	Buy	$126.00	High
12/15/2020	SVB Leerink	Boost Target	Market Perform	$91.00 ➝ $97.00	Low
11/30/2020	Bank of America	Downgrade	Buy ➝ Neutral	$123.00 ➝ $126.00	High
11/24/2020	SVB Leerink	Boost Target	Market Perform	$90.00 ➝ $91.00	Low
11/16/2020	Berenberg Bank	Reiterated Rating	Buy	$126.00	Medium
11/10/2020	JPMorgan Chase & Co.	Set Target	Neutral	$90.00	Medium
11/10/2020	SVB Leerink	Boost Target	Market Perform	$64.00 ➝ $90.00	High
10/29/2020	Commerzbank	Initiated Coverage	Buy	$119.00	High
10/14/2020	SVB Leerink	Boost Target	Positive ➝ Market Perform	$62.00 ➝ $69.00	High
9/22/2020	Berenberg Bank	Reiterated Rating	Buy	$98.00	Medium
8/6/2020	SVB Leerink	Boost Target	Market Perform	$42.00 ➝ $69.00	High
8/3/2020	Berenberg Bank	Initiated Coverage	Buy	$98.00	Medium
7/27/2020	HC Wainwright	Reiterated Rating	Hold		Low
7/21/2020	Bank of America	Upgrade	Neutral ➝ Buy	$71.00 ➝ $105.00	Low
7/20/2020	Bank of America	Upgrade	Neutral ➝ Buy	$71.00 ➝ $105.00	Low
7/14/2020	HC Wainwright	Reiterated Rating	Hold		High
7/2/2020	Bryan, Garnier & Co	Boost Target		$50.00 ➝ $62.00	High
7/2/2020	SVB Leerink	Boost Target	Positive ➝ Market Perform	$37.00 ➝ $42.00	High
6/30/2020	HC Wainwright	Downgrade	Buy ➝ Neutral		Medium
6/25/2020	HC Wainwright	Lower Target	Buy	$69.00 ➝ $63.00	High
5/19/2020	HC Wainwright	Upgrade	Neutral ➝ Buy	$48.00 ➝ $69.00	High
4/28/2020	Bank of America	Downgrade	Buy ➝ Neutral	$51.00	Medium
4/13/2020	HC Wainwright	Reiterated Rating	Neutral	$30.00 ➝ $48.00	High
3/18/2020	JPMorgan Chase & Co.	Downgrade	Overweight ➝ Neutral	$23.00 ➝ $33.00	High
3/17/2020	HC Wainwright	Reiterated Rating	Hold	$30.00	High
3/9/2020	HC Wainwright	Initiated Coverage	Neutral	$30.00	High
1/22/2020	UBS Group	Downgrade	Buy ➝ Neutral	$21.00 ➝ $35.00	Medium
11/5/2019	Wolfe Research	Initiated Coverage	Outperform	$21.00 ➝ $21.00	Low
11/4/2019	SVB Leerink	Initiated Coverage	Outperform		High
11/4/2019	Berenberg Bank	Initiated Coverage	Buy	$25.00	High
11/4/2019	Bank of America	Initiated Coverage	Buy ➝ Buy	$21.00 ➝ $21.00	High
11/4/2019	JPMorgan Chase & Co.	Initiated Coverage	Overweight	$23.00	High
11/4/2019	UBS Group	Initiated Coverage	Buy	$21.00	High

(Data available from 4/24/2019 forward)

News Sentiment Rating

0.98 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

18 very positive mentions
13 positive mentions
1 negative mentions
0 very negative mentions

Mentions as of

9/27/2023

12 very positive mentions
13 positive mentions
5 negative mentions
1 very negative mentions

Mentions as of

10/27/2023

5 very positive mentions
11 positive mentions
2 negative mentions
0 very negative mentions

Mentions as of

11/26/2023

9 very positive mentions
20 positive mentions
3 negative mentions
0 very negative mentions

Mentions as of

12/26/2023

7 very positive mentions
23 positive mentions
3 negative mentions
3 very negative mentions

Mentions as of

1/25/2024

20 very positive mentions
38 positive mentions
7 negative mentions
2 very negative mentions

Mentions as of

2/24/2024

10 very positive mentions
50 positive mentions
10 negative mentions
4 very negative mentions

Mentions as of

3/25/2024

14 very positive mentions
8 positive mentions
1 negative mentions
0 very negative mentions

Mentions as of

4/24/2024

Current Sentiment

Recent Stories by Sentiment

Very Negative

No very negative mentions tracked during this time.

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer. It develops BNT122, which is in Phase II clinical trial for first-line melanoma and in Phase I clinical trial to treat multiple solid tumors; BNT131 that is in Phase I clinical trial for multiple solid tumors; BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors; BNT151, BNT152, and BNT153 to treat solid tumors; BNT211 to treat multiple solid tumors, and BNT221 for pancreatic and other cancers; BNT311 which are in Phase II clinical trial to treat metastatic non-small cell lung cancer and Phase I/II clinical trial to treat multiple solid tumors; and BNT312, which is in Phase 2 clinical trial to treat multiple solid tumors, as well as ONC-392, which is in Phase III clinical trial to treat ovarian cancer and Phase I/II clinical trial to treat multiple solid tumors. It develops BNT321, an IgG1 monoclonal antibody in Phase I clinical trial for pancreatic cancer; BNT411, a small molecule immunomodulator product candidate in Phase I clinical trial for solid tumors; BNT322, which is in Phase I/Ib clinical trial for multiple solid tumors; and prophylactic vaccine for shingles, malaria, tuberculosis, HSV-2, and other infectious diseases. It has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd; and Ryvu Therapeutics S.A. BioNTech SE was incorporated in 2008 and is based in Mainz, Germany.

Today's Range

Now: $88.09

$87.82

$89.45

50 Day Range

MA: $91.05

$86.17

$96.30

52 Week Range

Now: $88.09

$85.21

$125.83

Volume

280,562 shs

Average Volume

671,110 shs

Market Capitalization

$20.94 billion

P/E Ratio

21.38

Dividend Yield

N/A

Beta

0.23

Frequently Asked Questions

What sell-side analysts currently cover shares of BioNTech?: The following Wall Street sell-side analysts have issued reports on BioNTech in the last year: BMO Capital Markets, Canaccord Genuity Group Inc., Deutsche Bank Aktiengesellschaft, HC Wainwright, HSBC Holdings plc, JPMorgan Chase & Co., Morgan Stanley, Oppenheimer Holdings Inc., Redburn Partners, The Goldman Sachs Group, Inc., and UBS Group AG.
View the latest analyst ratings for BNTX.
What is the current price target for BioNTech?: 10 Wall Street analysts have set twelve-month price targets for BioNTech in the last year. Their average twelve-month price target is $120.40, suggesting a possible upside of 36.7%. Canaccord Genuity Group Inc. has the highest price target set, predicting BNTX will reach $171.00 in the next twelve months. JPMorgan Chase & Co. has the lowest price target set, forecasting a price of $90.00 for BioNTech in the next year.
View the latest price targets for BNTX.
What is the current consensus analyst rating for BioNTech?: BioNTech currently has 1 sell rating, 5 hold ratings and 4 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in BNTX, but not buy more shares or sell existing shares.
View the latest ratings for BNTX.
What other companies compete with BioNTech?: Other companies that are similar to BioNTech include argenx, Biogen, Neurocrine Biosciences, Repligen and Qiagen. Learn More about companies similar to BioNTech.
How do I contact BioNTech's investor relations team?: BioNTech's physical mailing address is AN DER GOLDGRUBE 12, MAINZ 2M, 55131. The company's listed phone number is 49-61-31908-40 and its investor relations email address is [email protected]. The official website for BioNTech is www.biontech.de. Learn More about contacing BioNTech investor relations.

BioNTech - BNTX Stock Price Target and Predictions

Analyst Price Target for BNTX

Current Consensus is Hold

Past Monthly Recommendations

Latest Recommendations

News Sentiment Rating

0.98 (Buy)

News Sentiment Over Time

Current Sentiment

Recent Stories by Sentiment

Very Negative

Negative

Positive

Very Positive

Today's Range

50 Day Range

52 Week Range

Volume

Average Volume

Market Capitalization

P/E Ratio

Dividend Yield

Beta

Frequently Asked Questions

What sell-side analysts currently cover shares of BioNTech?

What is the current price target for BioNTech?

What is the current consensus analyst rating for BioNTech?

What other companies compete with BioNTech?

How do I contact BioNTech's investor relations team?